On Tuesday, Heron Therapeutics Inc (NASDAQ: HRTX) was -3.77% drop from the session before settling in for the closing price of $2.12. A 52-week range for HRTX has been $1.04 – $3.73.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 48.68% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 80.56%. With a float of $151.11 million, this company’s outstanding shares have now reached $152.43 million.
In an organization with 122 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 69.54%, operating margin of -2.26%, and the pretax margin is -4.93%.
Heron Therapeutics Inc (HRTX) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Heron Therapeutics Inc stocks. The insider ownership of Heron Therapeutics Inc is 0.95%, while institutional ownership is 82.19%.
Heron Therapeutics Inc (HRTX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 80.56% per share during the next fiscal year.
Heron Therapeutics Inc (NASDAQ: HRTX) Trading Performance Indicators
You can see what Heron Therapeutics Inc (HRTX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.76. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.10.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.06, a number that is poised to hit -0.01 in the next quarter and is forecasted to reach 0.07 in one year’s time.
Technical Analysis of Heron Therapeutics Inc (HRTX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.9 million. That was inferior than the volume of 1.63 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 30.75%.
During the past 100 days, Heron Therapeutics Inc’s (HRTX) raw stochastic average was set at 37.86%, which indicates a significant increase from 5.45% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.11 in the past 14 days, which was lower than the 0.14 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.05, while its 200-day Moving Average is $1.88. However, in the short run, Heron Therapeutics Inc’s stock first resistance to watch stands at $2.11. Second resistance stands at $2.18. The third major resistance level sits at $2.22. If the price goes on to break the first support level at $2.00, it is likely to go to the next support level at $1.96. The third support level lies at $1.89 if the price breaches the second support level.
Heron Therapeutics Inc (NASDAQ: HRTX) Key Stats
There are 152,564K outstanding shares of the company, which has a market capitalization of 311.23 million. As of now, sales total 144,290 K while income totals -13,580 K. Its latest quarter income was 38,900 K while its last quarter net income were 2,640 K.
